CVS Health (NYSE:CVS) reported its Q3 results last week, with EPS of $2.09 coming in better than the Street estimate of $2.00. Revenue was $81.16 billion, beating the Street estimate of $76.76 billion.

The quarterly results were highlighted by the strength across all segments, with management continuing to highlight momentum in individual Medicare Advantage and duals as membership grew 10.5% year-over-year, outpacing the industry.

For fiscal 2022, the company expects EPS to be in the range of $8.55-$8.65, compared to the Street estimate of $8.55.